$1.21
0.82% yesterday
Nasdaq, May 13, 10:11 pm CET
ISIN
US10501E2019
Symbol
BCLI

Brainstorm Cell Therapeutics Inc. Stock price

$1.21
+0.43 55.91% 1M
+0.04 3.42% 6M
-1.06 46.70% YTD
-7.01 85.28% 1Y
-39.59 97.03% 3Y
-83.69 98.57% 5Y
-55.49 97.87% 10Y
Nasdaq, Closing price Tue, May 13 2025
-0.01 0.82%
ISIN
US10501E2019
Symbol
BCLI
Sector

Key metrics

Market capitalization $8.78m
Enterprise Value $9.61m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.69m
Cash position $190.00k
EPS (TTM) EPS $-2.32
P/E forward negative
Short interest 5.06%
Show more

Is Brainstorm Cell Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Brainstorm Cell Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Brainstorm Cell Therapeutics Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Brainstorm Cell Therapeutics Inc.:

Buy
100%

Financial data from Brainstorm Cell Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.24 0.24
11% 11%
-
-0.24 -0.24
11% 11%
-
- Selling and Administrative Expenses 6.80 6.80
35% 35%
-
- Research and Development Expense 4.41 4.41
58% 58%
-
-11 -11
46% 46%
-
- Depreciation and Amortization 0.24 0.24
11% 11%
-
EBIT (Operating Income) EBIT -12 -12
45% 45%
-
Net Profit -12 -12
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Brainstorm Cell Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Brainstorm Cell Therapeutics Inc. Stock News

Neutral
PRNewsWire
7 days ago
NEW YORK , May 7, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2025, and provide a corporate update, at 8:30 a.m. Eastern Time on Thursday, May 15, 2025.
Neutral
PRNewsWire
8 days ago
Presentation of biomarker findings from cerebrospinal fluid analyses Workshop on adaptive and decentralized ALS trial design Panel on clinical trial access and the role of patient and caregiver engagement NEW YORK , May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participa...
Neutral
PRNewsWire
15 days ago
New findings highlight impact of UNC13A genotype on treatment response in ALS NEW YORK , April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS research centers, today announced the acceptance of new pharmacogenomic data for oral presentation of new findings on N...
More Brainstorm Cell Therapeutics Inc. News

Company Profile

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Head office United States
CEO Chaim Lebovits
Employees 27
Founded 2000
Website www.brainstorm-cell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today